Please log in to get access to this content
Dr. Luis Paz-Ares and Prof. Andrea Ardizzoni discuss the top small-cell lung cancer abstracts presented at ESMO 2023.
Abstracts discussed include:
- LBA92 – DeLLphi-301 (tarlatamab)
https://www.annalsofoncology.org/article/S0923-7534(23)04238-2/fulltext - 1989MO – LUPER study (lurbinectedin in combination with pembrolizumab)
https://www.annalsofoncology.org/article/S0923-7534(23)02057-4/fulltext - 1990MO - TROPiCS-03 basket trial (sacituzumab govitecan)
https://www.annalsofoncology.org/article/S0923-7534(23)02058-6/fulltext - LBA93 – EXTENTORCH (toripalimab plus chemotherapy vs placebo plus chemotherapy)
https://www.annalsofoncology.org/article/S0923-7534(23)04260-6/fulltext - 1988MO - TREASURE trial (atezolizumab with vs without thoracic radiotherapy)
https://www.annalsofoncology.org/article/S0923-7534(23)02056-2/fulltext
Presentation date: Tuesday 24th October 2023
Speakers
- Dr. Luis Paz-Ares
University Hospital October 12, Madrid, Spain. Read more - Prof. Andrea Ardizzoni
University Bologna, Italy. Read more
Speaker disclosures
Dr. Luis Paz-Ares
- Speaker fees: AZ, Beigene, BMS, Daichii, Lilly, Medscape, MSD, PER, Pharmamar, Roche.
- Board member: Altum sequencing, Genomica, Stab Therapeutics.
- Advisory boards: Amgen, AZ, Bayer, Beigene, BMS, Daichii, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, Pharmamar, Roche, Sanofi, Takeda.
- Other: Altum sequencing, Genomica, ONCOSUR.
- Personal: Altum sequencing, Amgen, AZ, Bayer, Beigene, BMS, Daichii, Genomica, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Stab Therapeutics, Amgen.
- Institutional: Alkermes, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
- Coordinating PI: Alkermes, Amgen, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
- Financial interest: Alkermes, Amgen, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
Prof. Andrea Ardizzoni
- Speaker fees: BMS, Astra Zeneca, MSD, Eli Lilly, Novartis
- Advisory boards: Janssen, AstraZeneca, BMS, Sanofi, Eli Lilly, Takeda, Bayer, Novartis, MSD
Financial disclosure
This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Disclaimer
Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.